# Aptus Pharma (NSE: APPL) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/APPL · Pivot · prices to 19 Oct 2026

With a market capitalisation of ₹377 Cr, it ranks 1940th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Medical Distribution.

Its return on equity was 19.8% in FY26. Promoters held 72.89% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Market cap | ₹377 Cr |
| ROE | 19.8% (FY26) |
| ROCE | 29.6% (FY26) |
| Debt to equity | 0.31 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY26 | ₹47 Cr | ₹5 Cr |
| FY25 | ₹25 Cr | ₹3 Cr |
| FY24 | ₹18 Cr | ₹1 Cr |
| FY23 | ₹14 Cr | ₹0 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 72.89%
- Non-institutions: 27.11%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Asarfi Hospital](https://app.pivotnow.in/stock/ASARFI) | — | ₹446 Cr | — | — |
| [Jenburkt Pharma](https://app.pivotnow.in/stock/JENBURPH) | ₹905.20 | ₹399 Cr | 11.5 | — |
| [Transchem](https://app.pivotnow.in/stock/TRANSCHEM) | — | ₹391 Cr | — | — |
| [Medicamen Biotech](https://app.pivotnow.in/stock/MEDICAMEQ) | ₹273.35 | ₹371 Cr | 37.9 | — |
| [Astal  Lab](https://app.pivotnow.in/stock/ASTALLTD) | — | ₹358 Cr | — | — |
| [Aarey Drugs & Pharmaceuticals](https://app.pivotnow.in/stock/AAREYDRUGS) | ₹114.47 | ₹325 Cr | 82.4 | — |

## Questions and answers

### What is the market cap of Aptus Pharma?

Aptus Pharma's market capitalisation is ₹377 Cr (₹377 Cr) at the 19 Oct 2026 close, ranking 1940th among the NSE companies Pivot tracks.

### What is the ROE and ROCE of Aptus Pharma?

Return on equity was 19.8% in FY26 and return on capital employed was 29.6% in FY26 (standalone figures).

### Is Aptus Pharma a debt-free company?

No. Aptus Pharma's debt-to-equity ratio was 0.31 in FY26, with total debt of ₹1 Cr.

### What is the shareholding pattern of Aptus Pharma?

As of 30 Jun 2026: promoters 72.89%, non-institutions 27.11%.

### Who are Aptus Pharma's competitors?

The listed Pharma & Healthcare companies closest to Aptus Pharma by market cap are Asarfi Hospital, Jenburkt Pharma, Transchem, Medicamen Biotech, Astal  Lab and Aarey Drugs & Pharmaceuticals.

### Is Aptus Pharma a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Aptus Pharma's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on APPL against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.